Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Polysulfated Glycosaminoglycan

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Solution) American Regent, Inc. Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Polysulfated Glycosaminoglycan

Polysulfated Glycosaminoglycan

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Liquid (Solution) Rx required 100% reference complete

Species: Both

Manufacturer: American Regent, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Polysulfated Glycosaminoglycan

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints. Species commonly shown: Both, Horse, Not For Meat Production, Adults.

Generic name
Polysulfated Glycosaminoglycan
Brand names
Adequan® Injectable, Adequan® i.m. Multi-Dose Adequan® i.m., Adequan® Canine, Adequan Canine
Manufacturer
American Regent, Inc.
Species
Both, Horse, Adults, Dog
Dosage forms
Liquid (Solution)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Adequan® Injectable Adequan® i.m. Multi-Dose Adequan® i.m. Adequan® Canine Adequan Canine adequan i.m.
Dosage forms
Liquid (Solution)

Indications / Uses

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eating, Lethargy (see also Central nervous system depression in Neurological).

FAQ

Both, Horse, Not For Meat Production, Adults, Dog

Yes. Roxee shows this as prescription-only.

Liquid (Solution)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only
  • Not for intra-articular use
  • Do not mix with other drugs or solvents
  • PSGAG is a synthetic heparinoid
  • do not use in dogs with known or suspected bleeding disorders
  • Do not exceed recommended dose or regimen
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Elevated gamma-glutamyl transferase (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Polysulfated Glycosaminoglycan; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-072107
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 29 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-072107
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-072107
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Elevated gamma-glutamyl transferase (1 reports), Elevated creatinine (1 reports), Elevated C-reactive protein (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (2), Behavior (2), Other (24)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (28 reports), Cat (4 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (2), Retriever - Labrador (1), Bloodhound (1), Siberian Husky (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Polysulfated Glycosaminoglycan fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Not for use in horses intended for food, Safe use in breeding animals has not been established, Do not use in horses intended for human consumption, Safe use in breeding animals or in lactating mares has not been established, For Intramuscular use in horses only

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Polysulfated Glycosaminoglycan brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-072107 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Elevated gamma-glutamyl transferase (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Adults, Dog, Horse
Indication / use
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Form / route / dose
Form: Liquid (Solution)
Route: Intra-Articular, Intramuscular
Confirm product label and patient-specific plan.
Warnings
  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts t…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: American Regent, Inc.
Form: Liquid (Solution)
Identifiers:
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Source metadata:

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
23
Matching reports
10
Active filters
1
Selected filters
Body system: Digestive Clear
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-013535

Received 2026-03-18 · MSK · MSK

Non-serious
Species
Dog
Breed
Retriever - Labrador
Sex
Female Neutered
Region
USA
Reactions
Anaemia NOSLeukopenia NOSNeutropeniaLethargy (see also Central nervous system depression in Neurological)AnorexiaDiarrhoeaLymphadenopathyEnteritisAbnormal radiograph findingOther abnormal test result NOSUrinary tract infectionIncreased band neutrophiliaPain NOSWobblinessTiredness
Body systems
OtherNeurologicDigestive
Outcomes
Ongoing

USA-USFDACVM-2026-US-012695

Received 2026-03-13 · MSK · MSK

Serious
Species
Dog
Breed
Dalmatian
Size / weight
50-99 lb (36.741 Kilogram)
Age
8+ years (1 Year)
Sex
Male Neutered
Region
USA
Reactions
AgitationDroolingFebrilePantingAnaphylaxisUnwellDecreased appetiteUrinary incontinenceVomitingDiarrhoeaLeukocytosis NOSNeutrophiliaLymphocytosisMonocytosisElevated globulinsElevated serum alkaline phosphatase (ALP)Anaemia NOSElevated alanine aminotransferase (ALT)Elevated C-reactive proteinAggressionUrolithiasisAutoimmune disorder NOSThrombocytopenia
Body systems
OtherDigestiveBehavior
Outcomes
Ongoing

USA-USFDACVM-2026-US-012380

Received 2026-02-18 · MSK · MSK

Non-serious
Species
Dog
Breed
Pit Bull
Size / weight
50-99 lb (36.106 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Neutered
Region
USA
Reactions
VomitingDiarrhoea
Body systems
Digestive
Outcomes
Ongoing

USA-USFDACVM-2025-US-075421

Received 2025-12-29 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - German
Size / weight
25-49 lb (20.865 Kilogram)
Age
8+ years (11 Year)
Sex
Female Unknown
Region
USA
Reactions
Emesis (multiple)Not eatingLethargy (see also Central nervous system depression in Neurological)Reluctant to moveSeizure NOS
Body systems
DigestiveOtherNeurologic
Outcomes
Ongoing

USA-USFDACVM-2025-US-074217

Received 2025-12-17 · MSK · MSK

Serious
Species
Dog
Breed
Retriever - Chesapeake Bay
Size / weight
50-99 lb (35.743 Kilogram)
Age
4-7 years (4 Year)
Sex
Female Neutered
Region
USA
Reactions
VomitingAnorexiaLoose stoolNeutrophiliaDehydrationLow platelet count
Body systems
DigestiveOther
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-073464

Received 2025-12-12 · MSK · MSK

Serious
Species
Dog
Breed
Retriever - Labrador
Size / weight
50-99 lb (37.83 Kilogram)
Age
8+ years (11 Year)
Sex
Male Neutered
Region
USA
Reactions
AnaphylaxisSeizure NOSVomitingCollapse NOS (see also Cardio-vascular and Neurological disorders)Loose bowelCongestion of mucous membraneLow blood pressureDecreased body temperature
Body systems
OtherNeurologicDigestive
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-074767

Received 2025-12-02 · MSK · MSK

Non-serious
Species
Dog
Breed
Shepherd Dog - Australian
Size / weight
25-49 lb (11.79 Kilogram)
Age
8+ years (12.92 Year)
Sex
Male Neutered
Region
USA
Reactions
Lethargy (see also Central nervous system depression in Neurological)InappetenceElevated blood urea nitrogen (BUN)Vomiting
Body systems
NeurologicOtherDigestive
Outcomes
Ongoing

USA-USFDACVM-2025-US-072107

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - German
Size / weight
50-99 lb (40.1 Kilogram)
Age
8+ years (10.5 Year)
Sex
Male Neutered
Region
USA
Reactions
VocalisationAbnormal tail posturePain NOSWeight lossDecreased appetiteVomitingChewing disorderPantingTremblingLying downAnxietyExcessive chewing, licking and/or groomingMuscle atrophy (see also Muscle wasting)Musculoskeletal disorder NOSAbnormal radiograph findingSpondylosisJoint effusionElevated gamma-glutamyl transferase (GGT)LymphopeniaLethargy (see also Central nervous system depression in Neurological)Thoracic painDeath by euthanasiaMedication error NOS
Body systems
OtherDigestiveBehaviorNeurologic
Outcomes
Euthanized

USA-USFDACVM-2025-US-069922

Received 2025-11-21 · MSK · MSK

Serious
Species
Cat
Breed
Cat (unknown)
Sex
Male Unknown
Region
USA
Reactions
Decreased appetiteLethargy (see also Central nervous system depression in Neurological)Diarrhoea
Body systems
DigestiveNeurologic
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-067552

Received 2025-11-13 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - German
Size / weight
50-99 lb (40.37 Kilogram)
Age
8+ years (9 Year)
Sex
Male Neutered
Region
USA
Reactions
Injection site painNot himself/herselfVomitingWobblinessUnexplained death
Body systems
OtherDigestive
Outcomes
Died

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
29
Species represented
2
Grouped by Body System
Digestive (4) · Loss of appetite, Drooling, Diarrhea Neurologic (2) · Unsteady walking (ataxia), Depression Behavior (2) · Anxiety, Aggression Other (24) · Elevated gamma-glutamyl transferase, Elevated creatinine, Elevated C-reactive protein
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (28) Cat (4)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Cat Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

7

FOI

4

Adequan® Canine

SPL · SPL

FDA Structured Product Label

Adequan® Canine

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
141-038
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Dog
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.

Dogs

Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan® i.m. Multi-Dose

SPL · SPL

FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® i.m.

SPL · SPL

FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® Injectable

SPL · SPL

FDA Structured Product Label

Adequan® Injectable

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
136-383
Status
RX
Form
Liquid (Solution)
Route
Intra-Articular
Species
Horse
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan Canine SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Adequan Canine. Use the source link for the full official labeling record.

adequan i.m. SPL

SPL · Structured Product Label

FDA Structured Product Label XML for adequan i.m.. Use the source link for the full official labeling record.

Adequan i.m. SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Adequan i.m.. Use the source link for the full official labeling record.

N141038_Orig_7_15_1997.pdf

FOI · FOI

N140901_Supp_9_12_1996.pdf

FOI · FOI

N140901 Orig_11_11_1989.pdf

FOI · FOI

UCM367650.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Adequan Canine Adequan i.m. adequan i.m.
Manufacturer mapping: American Regent, Inc.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Adults, Dog, Horse
Rx/OTC: RX
Form/route: Liquid (Solution) Intra-Articular, Intramuscular
Applications: NADA 141-038 • NADA 140-901 • NADA 136-383
NDC: Packages 10797-959-01 10797-975-01 10797-975-02 10797-995-01 10797-995-70 Products 10797
Documents: 4 (FOI: 4) • SPL: 4 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 98 Cat 18 View
Case summaries: 23 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Elevated gamma-glutamyl transferase (1) Elevated creatinine (1) Elevated C-reactive protein (1) Elevated alanine aminotransferase (1) Drooling (1) Discomfort NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Package NDC Product NDC Form / Route Status
10797-959-01 10797 -
10797-975-01 10797 -
10797-975-02 10797 -
10797-995-01 10797 -
10797-995-70 10797 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Adequan Canine SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N141038_Orig_7_15_1997.pdf • FOI summary • Official • June 28, 2018
    FDA FOI summary for application 141038
  • N140901 Orig_11_11_1989.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • N140901_Supp_9_12_1996.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • UCM367650.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 136383

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 126 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eat… (Clinical, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-12)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-02-12)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-06)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-05)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-04)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-03)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-02)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-08-01)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-31)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-30)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-29)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-28)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-27)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-26)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-25)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-25)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-22)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-07-22)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Adequan® Canine
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 141-038 Approved Jun 28, 2018
Adequan® i.m. Multi-Dose Adequan® i.m.
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 140-901 Approved Dec 7, 2017
Adequan® Injectable
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intra-Articular
American Regent, Inc. NADA 136-383 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.
Dogs
Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

FDA page: Open in Animal Drugs @ FDA

Species: Horse
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Drooling (1) • Dog Diarrhea (1) • Cat Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Depression (1) • Dog

Showing top 5 for Neurologic.

Behavior
Anxiety (1) • Dog Aggression (1) • Dog

Showing top 5 for Behavior.

Other
Elevated gamma-glutamyl transferase (1) • Dog Elevated creatinine (1) • Cat Elevated C-reactive protein (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Dog
Show more (19)
Discomfort NOS (1) • Dog Difficulty standing (1) • Dog Dehydration (1) • Dog Decreased haematocrit (1) • Cat Decreased drinking (1) • Dog Decreased body temperature (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Congestion of mucous membrane (1) • Dog Collapse NOS (1) • Dog Chewing disorder (1) • Dog Cardiac arrest (1) • Cat Bone and joint disorder NOS (1) • Dog Autoimmune disorder NOS (1) • Dog Anaphylaxis (1) • Dog Anaemia NOS (1) • Dog Agitation (1) • Dog Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Labrador, Female • Drug: MSK, Unknown • Reactions: Anaemia NOS, Leukopenia NOS, Neutropenia, Tiredness (lethargy), Loss of appetite… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013535
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Anaemia NOS Leukopenia NOS Neutropenia Tiredness (lethargy) Loss of appetite Diarrhea Lymphadenopathy Enteritis Abnormal radiograph finding Other abnormal test result NOS Urinary tract infection Increased band neutrophilia Pain NOS Wobbliness
Outcomes: Ongoing

Dog, Bloodhound, Male, 8 year, 68.492 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Limping, Pain NOS, Torn ligament, Joint swelling, Bone and joint disorder NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012892
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 68.492 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Limping Pain NOS Torn ligament Joint swelling Bone and joint disorder NOS Plantigrade posture Abnormal radiograph finding Medication error NOS
Outcomes: Ongoing

Dog, Siberian Husky, Male, 15 year, 28.576 kilogram • Drug: MSK, Injection, Unknown • Reactions: Death by euthanasia, Elevated symmetrical dimethylarginine, Reluctant to move, Polyuria • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2026-US-012589
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 28.576 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Injection
Reactions Reported:
Death by euthanasia Elevated symmetrical dimethylarginine Reluctant to move Polyuria
Outcomes: Euthanized

Dog, Dalmatian, Male, 10 year, 36.741 kilogram • Drug: MSK, Injection, solution, Unknown • Reactions: Agitation, Drooling, Febrile, Panting, Anaphylaxis… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012695
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 36.741 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Injection, solution
Reactions Reported:
Agitation Drooling Febrile Panting Anaphylaxis Unwell Decreased appetite Urinary incontinence Vomiting Diarrhea Leukocytosis NOS Neutrophilia Lymphocytosis Monocytosis Elevated globulins Elevated serum alkaline phosphatase Anaemia NOS Elevated alanine aminotransferase Elevated C-reactive protein Aggression Urolithiasis Autoimmune disorder NOS Thrombocytopenia
Outcomes: Ongoing

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Male, 9 year, 40.642 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Walking difficulty, Seizure NOS, Paralysis NOS, Death, Neurological disorder NOS • Outcome: Died

  • Report ID: USA-USFDACVM-2026-US-011582
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 40.642 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Walking difficulty Seizure NOS Paralysis NOS Death Neurological disorder NOS
Outcomes: Died

Cat, Domestic Shorthair, Female, 5 year, 5.5 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Immediate pain upon injection, Vocalisation, Medication error NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-009997
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 5.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Immediate pain upon injection Vocalisation Medication error NOS
Outcomes: Ongoing

Dog, Pit Bull, Female, 7 year, 36.106 kilogram • Drug: MSK, Unassigned, Unknown, Frequency: 1 per month • Reactions: Vomiting, Diarrhea • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012380
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 36.106 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
  • Frequency: 1 per month
Reactions Reported:
Vomiting Diarrhea
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 14 year, 5.244 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Hind limb ataxia, Weakness, Hind limb paresis, Urinary incontinence, Lack of efficacy - NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-006053
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 5.244 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Hind limb ataxia Weakness Hind limb paresis Urinary incontinence Lack of efficacy - NOS Proprioception loss Abnormal radiograph finding
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.